BCG helps biopharma companies fulfill their mission of delivering life-changing medicines and therapies, and take advantage of new technologies—including digital, data, and advanced analytics—in order to unlock innovation and bring new medicines to market faster.
Biopharma companies turn inspiration into innovation, discovering new medicines that improve and save lives—and they’re in the midst of transforming how they do it. The global pandemic pushed digital, data, and analytics to the forefront of the industry, shortening the time it takes to develop new medicines and bring them to patients. Next-generation capabilities are driving more rapid and effective manufacturing and supply chains. They’re also enabling the swift redesign of networks, the creation of new commercial models and patient-engagement ventures, and the pursuit of new value-creation opportunities through M&A. BCG’s biopharma consulting experts work with companies to accelerate all of these changes, building a foundation for strong growth and sustained value creation.
Our biopharma consultants work closely BCG’s specialty businesses on specific value-chain priorities, including digital supply chain, next-generation sales, personalization, and digital marketing. With our guidance, companies can rapidly scale new capabilities and ways of working through agile at scale, data and digital platforms, and our Build-Operate-Transfer approach. We also collaborate with technologists, scientists, programmers, engineers, and human-centered designers from BCG X, our tech build and design unit.
How BCG used a cascaded and holistic organization-design approach to help a global biotech firm reduce its gross labor and non-labor costs by 20%.
Read the full story
As many herald a new “golden era” of medicine, one roadblock remains: the daunting complexity of conducting clinical trials. Syneos Health saw the enormous potential AI held when it came to accelerating the process. Baba Shetty, President of Technology & Data Solutions at Syneos Health, explains how BCG X helped them pave the way.
Production Network Transformation. We guided a biopharma company through a multiyear transformation of its client network, production system, and supply model. The transformation included realigning site roles, combining portfolios, and pruning SKUs. It resulted in overall savings of more than $1.5 billion.
Increased Customer Engagement. At a major pharma company, topline growth for a previously underperforming product jumped 50% in a year after BCG used CRM, payer data, and other analytics to assess its promotional efforts and improve customer engagement.
R&D Innovation Strategy. We worked with a biopharma company to develop a holistic cell and gene therapy strategy. By collaborating, we identified entry points, current capabilities, possible M&A options, and needed investments, and created a high-level business plan.
Disease Management Platform. BCG X partnered with a global pharmaceutical company to launch a platform for patients with inflammatory bowel disease, providing live daily data to clinicians and medical researchers, and allowing for better treatment and drug development.
Integrated into our biopharma industry solutions are an array of proprietary tools, including benchmarks, databases, and other knowledge assets. Some highlights:
The Disease Deep Dive Navigator data-mining tool provides up-to-date market intelligence on developments in seven therapy areas. Clients use dashboards to track activity by therapy, company, R&D pipeline, and clinical trials.
The Biopharma M&A Suite is a series of tools that clients can use to identify potential products or technologies that could be a good match for their current or future portfolio and capabilities.
The BCOMM Benchmark is a database of key metrics for European and US industry players that helps clients optimize their own commercial organizational structure and operating models. It includes organizational productivity ratios by geography and function, resource strength, and activity allocation by geography.
The External Supply Benchmark is a database of external supply metrics for outsourcing manufacturing operations to third-party suppliers, including data on corporate portfolio and performance, organization and operating models, and tech transfers. BCG hosts an annual companion event with top biopharma industry suppliers.
The Yield Optimization Tool Model compiles sensor and process data and then applies machine learning to predict and optimize biopharma manufacturing yield based on key drivers.
The Real-Time Demand Forecasting tool is part of Data Intelligence AI by BCG X’s high-frequency data and analytics platform. It uncovers rapid shifts in demand and source of demand, allowing for dynamic planning and resource allocation. Forecasts for trends come from sophisticated proprietary models and data visualization.
BCG’s second annual report reviews the growth of new drug modalities over the past year and addresses the potential impact on the biopharmaceutical industry.
The medical aesthetics industry is growing rapidly, but it is not homogenous. Companies need to understand the varying needs of key consumer personas.
The cash generics market has the potential to become a $15 billion market by 2030. Here’s how incumbents and new entrants should prepare.
By leveraging innovative business models and partnerships, biopharma companies could reach patients in low- and middle-income countries at no extra cost.
The IRA provisions concerning the pricing of drugs for Medicare patients are creating new economic realities for health care players.
New GenAI offerings can benefit virtually every aspect of an organization, boosting efficiency and productivity in areas ranging from R&D to commercial activities.
